Abstract
New drugs active against drug-resistant tuberculosis are urgently needed to extend the range of TB treatment options to cover drug resistant infections. Quinoxaline derivatives show very interesting biological properties (antibacterial, antiviral, anticancer, antifungal, antihelmintic, insecticidal) and evaluation of their medicinal chemistry is still in progress. In this review we report the properties and the recent developments of quinoxaline 1,4-di-N-oxide derivatives as potential anti-tuberculosis agents. Specific agents are reviewed that have excellent antitubercular drug properties, are active on drug resistant strains and non-replicating mycobacteria. The properties of select analogs that have in vivo activity in the low dose aerosol infection model in mice will be reviewed.
Keywords: Tuberculosis, quinoxaline, N-oxides, mycobacterium, drug-resistant, medicinal chemistry is, antitubercular drug properties, non-replicating mycobacteria, aerosol infection, drug resistance, HIV, compounds
Infectious Disorders - Drug Targets
Title: Quinoxaline 1,4-di-N-Oxide and the Potential for Treating Tuberculosis
Volume: 11 Issue: 2
Author(s): Esther Vicente, Raquel Villar, Silvia Perez-Silanes, Ignacio Aldana, Robert C. Goldman and Antonio Monge
Affiliation:
Keywords: Tuberculosis, quinoxaline, N-oxides, mycobacterium, drug-resistant, medicinal chemistry is, antitubercular drug properties, non-replicating mycobacteria, aerosol infection, drug resistance, HIV, compounds
Abstract: New drugs active against drug-resistant tuberculosis are urgently needed to extend the range of TB treatment options to cover drug resistant infections. Quinoxaline derivatives show very interesting biological properties (antibacterial, antiviral, anticancer, antifungal, antihelmintic, insecticidal) and evaluation of their medicinal chemistry is still in progress. In this review we report the properties and the recent developments of quinoxaline 1,4-di-N-oxide derivatives as potential anti-tuberculosis agents. Specific agents are reviewed that have excellent antitubercular drug properties, are active on drug resistant strains and non-replicating mycobacteria. The properties of select analogs that have in vivo activity in the low dose aerosol infection model in mice will be reviewed.
Export Options
About this article
Cite this article as:
Vicente Esther, Villar Raquel, Perez-Silanes Silvia, Aldana Ignacio, C. Goldman Robert and Monge Antonio, Quinoxaline 1,4-di-N-Oxide and the Potential for Treating Tuberculosis, Infectious Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187152611795589735
DOI https://dx.doi.org/10.2174/187152611795589735 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Computational Biology in Anti-Tuberculosis Drug Discovery
Infectious Disorders - Drug Targets A Novel Advanced Laboratory Diagnosis to Guide Tuberculosis Drug Therapy.
Recent Patents on Anti-Infective Drug Discovery Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Current Pharmaceutical Design of Antituberculosis Drugs: Future Perspectives
Current Pharmaceutical Design Fragment-Based Drug Discovery and Molecular Docking in Drug Design
Current Pharmaceutical Biotechnology IBD Modern Concepts, Nano Drug Delivery and Patents: An Update
Recent Patents on Nanomedicine Editorial [Hot Topic: Bacterial Vectors for Gene & Cell Therapy (Guest Editors: Mark Tangney & Cormac G.M. Gahan)]
Current Gene Therapy Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice
Current Pharmaceutical Design 1, 4-Dihydropyridines: A Class of Pharmacologically Important Molecules
Mini-Reviews in Medicinal Chemistry 4H-1,3-Benzothiazin-4-one a Promising Class Against MDR/XDR-TB
Current Topics in Medicinal Chemistry FtsZ: A Novel Target for Tuberculosis Drug Discovery
Current Topics in Medicinal Chemistry Closing the Gap: An Atomistic Structural and Functional Perspective of S. <i>mansoni</i> Universal Stress G4LZI3 Protein in Complex with Phenolic Compounds
Current Drug Discovery Technologies Targeting Bacterial Metalloenzymes: A New Strategy for the Development of Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Progress of Molecular Docking Simulations Applied to Development of Drugs
Current Bioinformatics Design, Synthesis and In Vitro Antimalarial Evaluation of New Quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using `In silico Pharmacology`
Current Protein & Peptide Science Agrobacterium-Mediated Transient Expression as an Approach to Production of Recombinant Proteins in Plants
Recent Patents on Biotechnology Prevalence of HIV Drug Resistance Mutation in the Northern Indian Population After Failure of the First Line Antiretroviral Therapy
Current HIV Research